Background: Blue light has no known toxic effects on human skin, but reduces the proliferative capacity of keratinocytes in vitro. We therefore investigated the efficacy of blue light in the treatment of psoriasis vulgaris (PV). Methods: Forty patients with mild to moderate PV and bilateral plaques were assigned to two groups. Group 1 (n = 20) received irradiation at home with blue light (light-emitting diode, LED, emission maximum: 420 nm) once daily for 4 weeks. In parallel, group 2 (n = 20) performed irradiations with another blue light device (LED emission maximum: 453 nm). The contralateral control plaques remained untreated in both groups. Results: Thirty-seven patients completed the trial. The main study parameter, the difference of Local Psoriasis Severity Index (LPSI) scores of the irradiated plaques compared to the control plaques, showed statistically significant improvement after 4 weeks of treatment in both groups [group 1 (420 nm): n = 17, p = 0.04; group 2 (453 nm): n = 20, p = 0.04]. Accordingly, plaque status as assessed by both the physicians and the patients improved continuously during the 4 weeks of treatment and steadily declined thereafter. Conclusion: Blue light appears to be a promising treatment modality in PV that warrants further evaluation in larger studies.

Keywords:
Blue light, Psoriasis vulgaris, Prospective randomized controlled trial
1.
Gudjonsson JE, Johnston A: Current understanding of the genetic basis of psoriasis. Expert Rev Clin Immunol 2009;5:433–443.
2.
Cooper SJ, Bowden GT: Ultraviolet B regulation of transcription factor families. Curr Cancer Drug Targets 2007;7:325–334.
3.
Liebmann J, Born M, Kolb-Bachofen V: Blue-light irradiation regulates proliferation and differentiation in human skin cells. J Invest Dermatol 2010;130:259–269.
4.
Taoufik K, Mavrogonatou E, Eliades T, Papagiannoulis L, et al: Effect of blue light on proliferation of human gingival fibroblasts. Dent Mater 2008;24:895–900.
5.
Hamilton FL, Car J, Lyons C, et al: Laser and other light therapies for the treatment of acne vulgaris: systematic review. Br J Dermatol 2009;160:1273–1285.
6.
Stritt A, Merk HF, Braathen LR, von Felbert V: Photodynamic therapy in the treatment of actinic keratosis. Photochem Photobiol 2008;84:388–398.
7.
Morton CA, McKenna KE, Rhodes LE, et al: Guidelines for the topical photodynamic therapy: update. Br J Dermatol 2008;159:1245–1266.
8.
Kleinpenning MM, Smits T, Frunt MHA, et al: Clinical and histological effects of blue light on normal skin. Photodermatol Photoimmunol Photomed 2010;26:16–21.
9.
Langley RG, Ellis CN: Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment and lattice system physician‘s global assessment. J Am Acad Dermatol 2004;51:563–569.
10.
Finlay AY, Khan GK: Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
11.
Choi JW, Choi JW, Kwon IH, Youn JI: High-concentration (20 µg·g–1) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial. Br J Dermatol 2010;162:1359–1364.
12.
Engelmann K, Funk RH: Cataract extraction and blue light-impact on the retina. Klin Monatsbl Augenheilkd 2009;226:829–838.
13.
Von Felbert V, Hoffmann G, Hoff-Lesch S, et al: Photodynamic therapy of multiple actinic keratosis: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes. Br J Dermatol 2010;163:607–615.
14.
Durand F, Staumont D, Bonnevalle A, et al: Ultraviolet A1 phototherapy for the treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis. Photodermatol Photoimmunol Photomed 2007;23:215–221.
15.
Flyström I, Stenberg B, Svensson A, Bergbrant IM: Methotrexate vs ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116–121.
16.
Maari C, Viau G, Bissonnette R: Repeated exposure to blue light does not improve psoriasis. J Am Acad Dermatol 2003;49:55–58.
17.
Kleinpenning M, Otero M, van Erp P, Gerritsen M, van de Kerkhof P: Efficacy of blue light vs. red light in the treatment of psoriasis: a double-blind, randomized comparative study. J Eur Acad Dermatol Venerol 2011, E-pub ahead of print.
18.
Ankri R, Friedman H, Savion N, Kotev-Emeth S, Breitbart H, Lubart R: Visible light induces nitric oxide (NO) formation in sperm and endothelial cells. Lasers Surg Med 2010;42:348–352.
19.
Krischel V, Bruch-Gerharz D, Suschek C, et al: Biphasic effect of exogenous nitric oxide on proliferation and differentiation in skin derived keratinocytes but not fibroblasts. J Invest Dermatol 1998;111:286–291.
20.
Lubart R, Eichler M, Lavi R, et al: Low-energy laser irradiation promotes cellular redox activity. Photomed Laser Surg 2005;23:3–9.
21.
Gerritsen MJ, Smits T, Kleinpenning MM, et al: Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009;218:193–202.
22.
Torchia D, Cappugi P: Intralesional photodynamic therapy: a comment on the ‘Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy’ by Gerritsen et al. Dermatology 2010;220:44–45.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.